Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast AML, Mikkael Sekeres and colleagues designed the...
"The MDS Hub allows you to access the most relevant updates in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information and expert opinions to all physicians practicing hemato-oncology."